GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PT UBC Medical Indonesia Tbk LABS.JK · IDR

Health Care · IDX · 🇮🇩 Indonesia

Compare

121

-0.82%

Close of 9 Nov 2026, in IDR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About PT UBC Medical Indonesia Tbk

Its shares trade on IDX under the ticker LABS.JK. It has been listed since 10 July 2024. In the fiscal year to 31 December 2025, it reported revenue of IDR 199.30bn and net income of IDR 13.51bn. At that date it held total assets of IDR 228.19bn and shareholders' equity of IDR 152.46bn.

PT UBC Medical Indonesia Tbk is a ID-based company operating in Health Care Providers & Services industry. The company is headquartered in Jakarta Timur, Dki Jakarta. The company went IPO on 2024-07-10. PT UBC Medical Indonesia Tbk is an Indonesia-based medical diagnostic company. The firm provides affordable medical diagnostic tests and instruments for the Indonesian healthcare market. The firm operates through two segments: Medical disposable and consumables, and Diagnostic and equipment. The company offers various products to detect and diagnose various diseases, such as tuberculosis, cervical cancer, newborn screening, COVID-19, health risk screening with artificial intelligence (AI) and molecular systems. Its products include NeoMoDX Molecular System, Airdoc, QIAstat-DX Analyzer, Care HPV System, Hybrid Capture 2 - HPV DNA Test, Revvity SARS-COV-2 RT PCR, Geneproof SARS-COV-2 PCR KIT, Quantiferon TB Gold Plus, Genoscholar, Ina TB, GSP Neonatal Kit, Delfia Neonatal Kit, Neonatal Sampling Paper and Victor2 D.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
10 Jul 2024
Employees
64

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Operates in the Health Care sector with a focus on medical diagnostic services.
  • Offers a range of products for disease detection including AI and molecular systems.
  • Has a clear segmentation into Medical disposable and consumables, and Diagnostic and equipment.

Weaknesses

  • Limited employee count of 64 full-time employees.
  • IPO occurred recently on 2024-07-10, indicating a new market presence.
  • Relies on a narrow product range for disease detection within the Indonesian market.

Opportunities

  • Expanding the use of AI and molecular systems in medical diagnostics.
  • Growing demand for affordable medical diagnostic tests in Indonesia.
  • Potential to expand product offerings beyond current disease detection services.

Threats

  • Competition from other medical diagnostic companies in Indonesia.
  • Dependence on the Indonesian healthcare market for revenue.
  • Rapid technological changes requiring continuous innovation in diagnostic tools.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.